biib-023
mAbexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2008 (NCT00771329)
Timeline
Indications
Mechanism of action
TNFSF12 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109598 ↗
Also known as
- biib023
- biib-023
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01930890 | Phase 2 | Nov 1, 2013 | Biogen |
| NCT01943513 | Phase 1 | Oct 1, 2013 | Biogen |
| NCT01499355 | Phase 2 | Jul 1, 2012 | Biogen |
| NCT01407406 | Phase 1 | Sep 1, 2011 | Biogen |
| NCT00771329 | Phase 1 | Oct 1, 2008 | Biogen |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Biogen | For profit | 5 | 5 | 2 | 2008 |
1 organizations
Page 1 / 1